Literature DB >> 19945799

Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid.

Siavash Toosi1, Jean-Claude Bystryn.   

Abstract

Bullous pemphigoid is an autoimmune blistering disease of the skin caused by autoantibodies directed against basement membrane zone adhesion molecules. Autoantibodies cannot fully explain several important features of the disease such as the difficulty transferring with the pathogenic autoantibodies, or the presence of heavy lesional infiltration of eosinophils and neutrophils that is necessary for disease production. There is increasing evidence that Th17 cells and the cytokines they release such as interleukin-17 are important regulators of innate and adaptive immune responses in many Th1 and/or Th2 mediated autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and allergic asthma. There is also evidence that Th17 cells have a role in pathogenesis of blistering skin diseases. Interleukin-17 is important in initiation and maintenance of many autoimmune reactions and it is involved in production of pro-inflammatory cytokines, matrix metalloproteinases, neutrophils, and eosinophils, all of which are important pathogenic factors in bullous pemphigoid. The hypothesis is that interleukin-17 has an important pathogenic role in BP and can describe features of the disease not explained by the autoantibody theory. This cytokine can be assessed in the blister fluid and sera of patients, and can be used as a marker of disease activity and response to therapy. The information obtained could also lead to the development of novel therapeutic strategies for this and other autoimmune blistering diseases. (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19945799     DOI: 10.1016/j.mehy.2009.10.038

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  6 in total

1.  Response of peripheral blood Th17 cells to inhaled Dermatophagoides pteronyssinus in patients with allergic rhinitis and asthma.

Authors:  Ieva Bajoriuniene; Kestutis Malakauskas; Simona Lavinskiene; Jolanta Jeroch; Edita Gasiuniene; Astra Vitkauskiene; Raimundas Sakalauskas
Journal:  Lung       Date:  2012-07-28       Impact factor: 2.584

2.  Bullous pemphigoid caused by contact allergy to bone cement: A case report.

Authors:  Sylvie M Franken; Thomas Rustemeyer
Journal:  Contact Dermatitis       Date:  2020-12-27       Impact factor: 6.600

3.  Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis.

Authors:  K Juczynska; A Wozniacka; E Waszczykowska; M Danilewicz; M Wagrowska-Danilewicz; J Wieczfinska; R Pawliczak; A Zebrowska
Journal:  Mediators Inflamm       Date:  2017-10-24       Impact factor: 4.711

Review 4.  Current Clinical Trials in Pemphigus and Pemphigoid.

Authors:  Kentaro Izumi; Katja Bieber; Ralf J Ludwig
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

5.  Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome.

Authors:  Julie Plée; Sébastien Le Jan; Jérôme Giustiniani; Coralie Barbe; Pascal Joly; Christophe Bedane; Pierre Vabres; François Truchetet; François Aubin; Frank Antonicelli; Philippe Bernard
Journal:  Sci Rep       Date:  2015-12-14       Impact factor: 4.379

6.  Expression of JAK3, STAT2, STAT4, and STAT6 in pemphigus vulgaris.

Authors:  K Juczynska; A Wozniacka; E Waszczykowska; M Danilewicz; M Wągrowska-Danilewicz; Agnieszka Zebrowska
Journal:  Immunol Res       Date:  2020-04       Impact factor: 2.829

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.